Both nongenomic and genomic effects are involved in estradiol's enhancing the phenotype of smooth muscle cells in cultured prostate stromal cells

Prostate

Volumn 70, Issue 3, 2010, Pages 317-332

  Zhang, Zhisong ^a   Wang, Liang ^a   Mei, Mei ^b,c   Zhu, Yan ^d   Du, Xiaoling ^a   Lee, Chung ^e   Park, Irwin ^e   Zhang, Ju ^a   Shi, Jiandang ^a  

^a NANKAI UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c TIANJIN UNIVERSITY   (China)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Estrogen; Genomic effect; Nongenomic effect; SMC

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ESTRADIOL; FULVESTRANT; MESSENGER RNA; NEUTRALIZING ANTIBODY; SMOOTHELIN; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOMICS; HUMAN; HUMAN CELL; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; STROMA CELL; UPREGULATION; WESTERN BLOTTING;

ANTIBODIES, NEUTRALIZING; CELL DIFFERENTIATION; CELLS, CULTURED; DRUG SYNERGISM; ESTRADIOL; ESTROGEN ANTAGONISTS; FLAVONOIDS; GENE EXPRESSION REGULATION; GENOME, HUMAN; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; PROSTATE; SERUM ALBUMIN, BOVINE; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 75649126564     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21066     Document Type: Article

References (44)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132(3):474-479.
2. Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K, Okajima E, Yoshida O, Kumazawa J, Gu FL, Lee C, Hsu TC, dela Cruz RC, Tantiwang A, Lim PH, Sheikh MA, Bapat SD, Marshall VR, Tajima K, Aso Y. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol 1997;4(1):40-46.
3. Bartsch G, Egender G, Hubscher H, Rohr H. Sonometrics of the prostate. J Urol 1982;127(6):1119-1121.
4. Suzuki K, Inaba S, Takeuchi H, Takezawa Y, Fukabori Y, Suzuki T, Imai K, Yamanaka H, Honma S. Endocrine environment of benign prostatic hyperplasia-Relationships of sex steroid hormone levels with age and the size of the prostate. Nippon Hinyokika Gakkai Zasshi 1992;83(5):664-671.
5. Krieg M, Nass R, Tunn S. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 1993;77(2):375-381.
6. vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, Dhar MD, Ganjam VK, Parmigiani S, Welshons WV. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 1997;94(5):2056-2061.
7. Nakhla AM, Khan MS, Romas NP, Rosner W. Estradiol causes the rapid accumulation of cAMP in human prostate. Proc Natl Acad Sci USA 1994;91(12):5402-5405.
8. Zhang J, Hess MW, Thurnher M, Hobisch A, Radmayr C, Cronauer MV, Hittmair A, Culig Z, Bartsch G, Klocker H. Human prostatic smooth muscle cells in culture: Estradiol enhances expression of smooth muscle cell-specific markers. Prostate 1997;30(2):117-129.
9. Smith P, Rhodes NP, Ke Y, Foster CS. Relationship between upregulated oestrogen receptors and expression of growth factors in cultured, human, prostatic stromal cells exposed to estradiol or dihydrotestosterone. Prostate Cancer Prostatic Dis 2004;7(1):57-62.
10. Bektic J, Wrulich OA, Dobler G, Kofler K, Ueberall F, Culig Z, Bartsch G, Klocker H. Identification of genes involved in estrogenic action in the human prostate using microarray analysis. Genomics 2004;83(1):34-44.
11. Timms BG, Petersen SL, vom Saal FS. Prostate gland growth during development is stimulated in both male and female rat fetuses by intrauterine proximity to female fetuses. J Urol 1999; 161(5):1694-1701.
12. Zhao GQ, Holterhus PM, Dammshauser I, Hoffbauer G, Aumuller G. Estrogen-induced morphological and immuno-histochemical changes in stroma and epithelium of rat ventral prostate. Prostate 1992;21(3):183-199.
13. Murakoshi M, Tagawa M, Inada R, Suzuki M. Effects of testosterone, and testosterone plus estrogen, in the castrated rat ventral prostate- Histopathological and immunocytochemical studies. Tokai J Exp Clin Med 1992;17(3-4):133-137.
14. Suzuki K, Ito K, Suzuki T, Honma S, Yamanaka H. Synergistic effects of estrogen and androgen on the prostate: Effects of estrogen on androgen- and estrogen-receptors, BrdU uptake, immunohistochemical study of AR, and responses to antiandrogens. Prostate 1995;26(3):151-163.
15. Fujimoto N, Suzuki T, Honda H, Kitamura S. Estrogen enhancement of androgen-responsive gene expression in hormoneinduced hyperplasia in the ventral prostate of F344 rats. Cancer Sci 2004;95(9):711-715.
16. Royuela M, de Miguel MP, Bethencourt FR, Sanchez-Chapado M, Fraile B, Arenas MI, Paniagua R. Estrogen receptors alpha and beta in the normal, hyperplastic and carcinomatous human prostate. J Endocrinol 2001;168(3):447-454.
17. Gaub MP, Bellard M, Scheuer I, Chambon P, Sassone-Corsi P. Activation of the ovalbumin gene by the estrogen receptor involves the fos-jun complex. Cell 1990;63(6):1267-1276.
18. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y, Kamada T. Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. J Biol Chem 1994;269(23):16433-16442.
19. Webb P, Lopez GN, Uht RM, Kushner PJ. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9(4):443-456.
20. Porter W, Saville B, Hoivik D, Safe S. Functional synergy between the transcription factor Sp1 and the estrogen receptor. Mol Endocrinol 1997;11(11):1569-1580.
21. Li C, Briggs MR, Ahlborn TE, Kraemer FB, Liu J. Requirement of Sp1 and estrogen receptor alpha interaction in 17beta-estradiolmediated transcriptional activation of the low density lipoprotein receptor gene expression. Endocrinology 2001;142(4): 1546-1553.
22. Duan R, Porter W, Safe S. Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: Role of estrogen receptor Sp1 complex formation. Endocrinology 1998;139(4): 1981-1990.
23. Safe S. Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 2001; 62:231-252.
24. Hennessy BA, Harvey BJ, Healy V. 17beta-Estradiol rapidly stimulates c-fos expression via the MAPK pathway in T84 cells. Mol Cell Endocrinol 2005;229(1-2):39-47.
25. Moor AN, Flynn JM, Gottipati S, Giblin FJ, Cammarata PR. 17beta-estradiol stimulates MAPK signaling pathway in human lens epithelial cell cultures preventing collapse of mitochondrial membrane potential during acute oxidative stress. Mitochondrion 2005;5(4):235-247.
26. Gu Q, Moss RL. 17 beta-Estradiol potentiates kainate-induced currents via activation of the cAMP cascade. J Neurosci 1996; 16(11):3620-3629.
27. Guo RX, Wei LH, Wang JL, Sun PM, Sun XL. Activation of phosphatidylinositol 3-kinase-protein kinase B (PI3K-PKB) induced by 17beta-estradiol in endometrial carcinoma cell (Ishikawa). Zhonghua Fu Chan Ke Za Zhi 2004;39(7):469-473.
28. Satake A, Takaoka M, Nishikawa M, Yuba M, Shibata Y, Okumura K, Kitano K, Tsutsui H, Fujii K, Kobuchi S, Ohkita M, Matsumura Y. Protective effect of 17beta-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway. Kidney Int 2008;73(3):308-317.
29. Samadi A, Carlson CG, Gueorguiev A, Cenedella RJ. Rapid, non-genomic actions of progesterone and estradiol on steady-state calcium and resting calcium influx in lens epithelial cells. Pflugers Arch 2002;444(6):700-709.
30. Muchekehu RW, Harvey BJ. Estradiol rapidly induces the translocation and activation of the intermediate conductance calcium activated potassium channel in human eccrine sweat gland cells. Steroids 2009;74(2):212-217.
31. Russell KS, Haynes MP, Sinha D, Clerisme E, Bender JR. Human vascular endothelial cells contain membrane binding sites for estradiol, which mediate rapid intracellular signaling. Proc Natl Acad Sci USA 2000;97(11):5930-5935.
32. Lu Q, Pallas DC, Surks HK, Baur WE, Mendelsohn ME, Karas RH. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci USA 2004;101(49): 17126-17131.
33. Schlegel A, Wang C, Pestell RG, Lisanti MP. Ligandindependent activation of oestrogen receptor alpha by caveolin-1. Biochem J 2001;359 (Pt 1):203-210.
34. Chambliss KL, Simon L, Yuhanna IS, Mineo C, Shaul PW. Dissecting the basis of nongenomic activation of endothelial nitric oxide synthase by estradiol: Role of ERalpha domains with known nuclear functions. Mol Endocrinol 2005;19(2):277-289.
35. Filardo EJ, Thomas P. GPR30: A seven-transmembrane-spanning estrogen receptor that triggers EGF release. Trends Endocrinol Metab 2005;16(8):362-367.
36. Zhang Z, Duan L, Du X,Ma H, Park I, Lee C, Zhang J, Shi J. The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK. Prostate 2008;68(5):508-516.
37. Bartsch G, Frick J, Ruegg I, Bucher M, Holliger O, Oberholzer M, Rohr HP. Electron microscopic stereological analysis of the normal human prostate and of benign prostatic hyperplasia. J Urol 1979;122(4):481-486.
38. Lee C, Sintich SM, Mathews EP, Shah AH, Kundu SD, Perry KT, Cho JS, Ilio KY, Cronauer MV, Janulis L, Sensibar JA. Transforming growth factor-beta in benign and malignant prostate. Prostate 1999;39(4):285-290.
39. Peehl DM, Sellers RG. Induction of smooth muscle cell phenotype in cultured human prostatic stromal cells. Exp Cell Res 1997;232(2):208-215.
40. Du XJ. Clues to understanding the role of estrogen receptors in mediating cardiovascular protection. Cardiovasc Res 2002;56(1): 4-7.
41. Herrington D. Role of estrogens, selective estrogen receptor modulators and phytoestrogens in cardiovascular protection. Can J Cardiol 2000;16(suppl E):5E-9E.
42. Muck AO, Seeger H, Korte K, Lippert TH. Cardiovascular protection by postmenopausal estrogen replacement therapy: Possible mechanisms of the estrogen action. Clin Exp Obstet Gynecol 1994;21(3):143-149.
43. Rozenberg S, Liebens I, Vandromme J, Hotimsky A, Van Rijsselberge M. Cardiovascular protection by estrogen: A hemodynamic mechanism? Int J Fertil Menopausal Stud 1994; 39(suppl 1):36-42.
44. Subah Packer C. Estrogen protection, oxidized LDL, endothelial dysfunction and vasorelaxation in cardiovascular disease: New insights into a complex issue. Cardiovasc Res 2007; 73(1):6-7.